Treatment of neuroendocrine tumours with 177Lu‐peptide receptor radionuclide therapy: Challenging clinical scenarios and their management. (25th January 2022)

• Record Type: Journal Article
• Authors: Navalkissoor, Shaunak; Toumpanakis, Christos; Caplin, Martyn; Gnanasegaran, Gopinath
• Is Part Of: Journal of neuroendocrinology. Volume 34:Number 4(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-01-25
• Subjects: 177Lu‐DOTATATE -- peptide receptor radionuclide therapy -- radioligand therapy; Neuroendocrinology -- Periodicals; 616.4
• DOI: 10.1111/jne.13088
• Languages: English
• ISSNs: 0953-8194

Abstract

Abstract: Peptide receptor radionuclide therapy (PRRT) for the treatment of patients with neuroendocrine tumours is usually well tolerated, with selection based on existing guidelines. However, there are various scenarios where the risk–benefit analysis of PRRT needs to be evaluated to limit any complications associated with PRRT. This review looks at 11 key scenarios where the risk–benefit of PRRT needs to be closely evaluated. Abstract : In this review, we look at 11 challenging scenarios involving 177 Lu‐peptide receptor radionuclide therapy and discuss the clinical risk, patient selection and treatment of these cases.